TWI BIOTECHNOLOGY, INC.
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- TWi Biotechnology, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06073132
- Locations
- 🇫🇷
Hopital Necker-Enfants Malades, Paris, France
🇬🇧University Hospitals Birmingham NHS Foundation Trust (UHB), Solihull, United Kingdom
🇺🇸Mission dermatology Center, Rancho Santa Margarita, California, United States
Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- TWi Biotechnology, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT05580042
- Locations
- 🇺🇸
Yale Center for Clinical Investigation, New Haven, Connecticut, United States
Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2021-11-29
- Lead Sponsor
- TWi Biotechnology, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT04468425
- Locations
- 🇨🇦
Syneos Health Facility, Québec, Canada
Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- TWi Biotechnology, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT04239846
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
🇨🇳Chang Gung Memorial Hospital, Taoyuan, Taiwan
A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients
- First Posted Date
- 2018-03-16
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- TWi Biotechnology, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03468322
- Locations
- 🇨🇳
Mackay Memorial Hospital, Hsinchu, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid
- Conditions
- Interventions
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- TWi Biotechnology, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03286582
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- TWi Biotechnology, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02994147
- Locations
- 🇨🇳
Tri-Service General Hospital, Taipei, Taiwan
A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- TWi Biotechnology, Inc.
- Target Recruit Count
- 127
- Registration Number
- NCT02287818
- Locations
- 🇨🇳
Taipei Veteran General Hospital (TVGH), Taipei, Taiwan
A Proof-of-Concept Study of AC-201 to Prevent Gout Flares
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- TWi Biotechnology, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT01712204
- Locations
- 🇨🇳
Veterans General Hospital, Taipei, Taiwan
Study of AC-201 in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- TWi Biotechnology, Inc.
- Target Recruit Count
- 259
- Registration Number
- NCT01276106
- Locations
- 🇨🇳
Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan
🇺🇸Jacksonville Impotence Treatment Center, Jacksonville, Florida, United States
🇨🇳Changhua Christian Hospital, Changhua, Taiwan